Latest filings (excl ownership)
6-K
Report of Foreign Private Issuer
16 Apr 24
6-K
Appendix 2A - Application for quotation of securities
15 Apr 24
6-K
Results of Extraordinary General Meeting
12 Apr 24
6-K
Report of Foreign Private Issuer
12 Apr 24
6-K
Alterity Therapeutics Receives a $3.9 million Research & Development Tax Incentive Refund
26 Mar 24
6-K
Report of Foreign Private Issuer
14 Mar 24
6-K
Report of Foreign Private Issuer
4 Mar 24
6-K
Appendix 2A - Application for quotation of securities
4 Mar 24
6-K
Results for announcement to the market
28 Feb 24
6-K
Report of Foreign Private Issuer
22 Feb 24
6-K
Report of Foreign Private Issuer
22 Feb 24
6-K
Report of Foreign Private Issuer
22 Feb 24
6-K
Report of Foreign Private Issuer
21 Feb 24
6-K
Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting
20 Feb 24
6-K
Report of Foreign Private Issuer
15 Feb 24
424B5
Prospectus supplement for primary offering
15 Feb 24
6-K
Report of Foreign Private Issuer
6 Feb 24
6-K
Report of Foreign Private Issuer
2 Feb 24
6-K
Not for release to US wire services or distribution in the United States
2 Feb 24
6-K
Report of Foreign Private Issuer
2 Feb 24
6-K
Appendix 4C – Q2 FY24 Quarterly Cash Flow Report
31 Jan 24
6-K
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
22 Jan 24
6-K
Report of Foreign Private Issuer
18 Jan 24
6-K
Report of Foreign Private Issuer
11 Jan 24
6-K
Alterity Therapeutics Launches Security Purchase Plan (SPP) with Continued Support from Institutional Shareholders
11 Jan 24
6-K
Not for release to US wire services or distribution in the United States
10 Jan 24
6-K
Report of Foreign Private Issuer
8 Jan 24
6-K
Not for release to US wire services or distribution in the United States
8 Jan 24
6-K
Report of Foreign Private Issuer
8 Jan 24
6-K
Report of Foreign Private Issuer
8 Jan 24
6-K
Update to previous announcement
5 Jan 24
6-K
Update to previous announcement
5 Jan 24
6-K
Alterity Therapeutics Announces Shareholder Approval of Tranche Two Placement and Security Purchase Plan
2 Jan 24
6-K
Report of Foreign Private Issuer
2 Jan 24
6-K
Report of Foreign Private Issuer
2 Jan 24
6-K
Results of Extraordinary General Meeting
29 Dec 23
6-K
Report of Foreign Private Issuer
29 Dec 23
6-K
Report of Foreign Private Issuer
21 Dec 23
6-K
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
21 Dec 23
6-K
Update to previous announcement
18 Dec 23
Latest ownership filings
SC 13D/A
Life Biosciences LLC
31 Oct 22
SC 13D/A
Life Biosciences LLC
26 Aug 22
SC 13D/A
Life Biosciences LLC
1 Aug 22
SC 13D/A
Life Biosciences LLC
21 Jul 22
SC 13D/A
Life Biosciences LLC
28 Mar 22
SC 13D/A
Life Biosciences LLC
4 Mar 22
SC 13D/A
Life Biosciences LLC
8 Jul 21
SC 13D/A
Life Biosciences LLC
25 Nov 20
SC 13D/A
Life Biosciences LLC
26 Oct 20
SC 13D/A
Life Biosciences LLC
6 Jul 20
SC 13D/A
Alterity Therapeutics LTD
23 Dec 19
SC 13D
Alterity Therapeutics LTD
18 Apr 19